Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) reached a new 52-week high during trading on Wednesday . The stock traded as high as $28.08 and last traded at $26.11, with a volume of 2883 shares trading hands. The stock had previously closed at $25.19.
Analyst Ratings Changes
A number of research firms have commented on BCAX. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a report on Tuesday. They issued a “buy” rating and a $48.00 price objective for the company. TD Cowen assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating for the company. RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday. Morgan Stanley assumed coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 target price for the company. Finally, Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set a “buy” rating and a $47.00 price target for the company. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Bicara Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $43.33.
View Our Latest Research Report on Bicara Therapeutics
Bicara Therapeutics Price Performance
Insider Activity at Bicara Therapeutics
Bicara Therapeutics Company Profile
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Recommended Stories
- Five stocks we like better than Bicara Therapeutics
- The Risks of Owning Bonds
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 3 Rising-Margin Stocks with Strong Growth Potential
- Breakout Stocks: What They Are and How to Identify Them
- 3 Recession-Resistant Stocks: Low Beta, High Margins, Low Debt
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.